The St. George\u2019s Respiratory Questionnaire<\/a> (SGRQ) is a globally recognized, disease-specific psychometric instrument engineered to evaluate health-related quality of life (HRQoL<\/a>) and functional impairment in patients diagnosed with chronic airflow limitation, most notably chronic obstructive pulmonary disease<\/a> (COPD), asthma<\/a>, and bronchiectasis. Developed in 1991 by Paul W. Jones and colleagues at St George\u2019s Hospital Medical School, University of London, the SGRQ addresses the critical dissociation between physiological biomarkers of airway obstruction (such as forced expiratory volume in one second<\/a>, FEV1<\/sub>) and patients’ everyday lived experiences, emotional well-being, and functional capacity. Comprising 50 items partitioned across two principal parts and yielding 76 individual responses, the questionnaire evaluates three distinct psychometric domains: Symptoms<\/em> (measuring the frequency, duration, and severity of respiratory distress), Activity<\/em> (evaluating physical activities that induce or are restricted by dyspnea), and Impacts<\/em> (capturing the broad psychosocial disruptions, panic, medication burden, and loss of perceived control provoked by chronic airway disease). The instrument employs a sophisticated empirical item-weighting methodology derived from Thurstonian scaling techniques, transforming responses into component scores and an aggregated Total score ranging from 0 (denoting zero functional impairment or optimal health status) to 100 (indicating maximal health impairment). Psychometric evaluations consistently confirm high internal consistency (Cronbach\u2019s alpha α = 0.88\u20130.94 for the Total score; subscales α = 0.70\u20130.89), robust test-retest reliability (intraclass correlation coefficients ≥ 0.80), and an internationally validated Minimal Clinically Important Difference (MCID) established at 4.0 units. With proven cross-cultural validity in more than 80 standardized linguistic adaptations, the SGRQ serves as a gold-standard primary and secondary endpoint in international clinical trials, pulmonary rehabilitation assessment, and longitudinal epidemiological research<\/span>.<\/p>\n St. George\u2019s Respiratory Questionnaire, SGRQ, chronic obstructive pulmonary disease, COPD, asthma, health-related quality of life, psychometrics, patient-reported outcome measures, dyspnea, functional impairment, Thurstonian weighting, clinical trials, pulmonary rehabilitation, minimal clinically important difference, respiratory health status<\/p>\n The St. George\u2019s Respiratory Questionnaire was originally conceptualized, designed, and psychometrically validated by a multidisciplinary team of pulmonary medicine clinicians, epidemiologists, and psychometric researchers at the Division of Physiological Medicine, St George\u2019s Hospital Medical School (now St George\u2019s, University of London), London, United Kingdom:<\/p>\n The primary purpose of the St. George\u2019s Respiratory Questionnaire is to provide a standardized, highly discriminative, and responsive patient-reported outcome measure (PROM<\/a>) designed to capture the unique health status, daily life limitations, and psychological distress of patients suffering from chronic obstructive pulmonary disorders. Prior to the development of the SGRQ, clinical evaluations of respiratory pathology relied almost exclusively upon objective physiological markers, notably spirometry (FEV1<\/sub>, forced vital capacity [FVC], and peak expiratory flow). However, extensive clinical research revealed that FEV1<\/sub> correlates poorly with subjective symptom perception, functional exercise capacity, affective distress, and social role limitation. The SGRQ was formulated precisely to bridge this clinical-pathological divide by quantifying the subjective health status and functional disability experienced by the individual.<\/p>\n In clinical trials, the SGRQ serves as an international regulatory endpoint for assessing the therapeutic efficacy of novel pharmacotherapies (such as long-acting muscarinic antagonists [LAMAs], long-acting beta-agonists [LABAs], inhaled corticosteroids [ICS], and biological agents targeting specific inflammatory pathways). Changes in SGRQ scores quantify whether a pharmacological intervention achieves clinical relevance beyond statistical significance, relying on its well-established Minimal Clinically Important Difference (MCID) of 4.0 units. A therapeutic reduction of 4 points or greater signifies a clinically perceptible improvement in patient daily function and symptom burden.<\/p>\n Beyond pharmacotherapy trials, the SGRQ is widely implemented in pulmonary rehabilitation<\/a> programs, surgical intervention evaluations (such as lung volume reduction surgery and bronchoscopic lung volume reduction), and longitudinal health services research. In clinical practice, the tool provides multidisciplinary healthcare teams\u2014comprising pulmonologists, respiratory physiotherapists, clinical psychologists, and occupational therapists\u2014with an item-level and domain-level profile of patient vulnerability. This granular insight facilitates tailored physical reconditioning, targeted behavioral and cognitive interventions to address breathlessness-induced panic, and longitudinal monitoring of disease progression and exacerbation recovery.<\/p>\n The SGRQ measures the overarching psychological and behavioral construct of disease-specific Health-Related Quality of Life<\/em> (HRQoL) in the context of chronic respiratory illness. In psychometric theory, HRQoL represents a multidimensional latent construct encompassing the subjective perception of physical, emotional, and social well-being as altered by an underlying medical condition and its medical management. The SGRQ operationalizes this latent construct across three correlated yet functionally distinct first-order domains:<\/p>\n The Symptoms component operationalizes the patient\u2019s perceived frequency, chronicity, and episodic severity of respiratory distress over a defined recall period (conventionally the preceding 12 months, or 1 to 3 months in acute and clinical trial variants). This domain captures cardinal clinical manifestations of chronic airway disease, including productive cough, phlegm\/sputum expectoration, wheezing, nocturnal breathlessness, and acute exacerbation events (referred to in the instrument as “chest attacks”). Psychometrically, this domain measures the baseline distress evoked by physical sensations. It captures not only symptom occurrence, but also the temporal pattern and unpredictability of attacks, which provoke anticipatory anxiety and hypervigilance regarding somatic respiratory cues.<\/p>\n The Activity component measures physical and functional restrictions directly attributable to dyspnea (breathlessness<\/a>). This domain focuses on the physical behaviors of daily living, differentiating between sedentary baseline states and varying gradients of exertion. It examines activities of daily living (ADLs) such as getting washed, dressing, ambulating within the domestic environment, walking outdoors on level ground, ascending stairs, climbing inclines, and engaging in leisure or manual labor. From a behavioral psychometric standpoint, the Activity subscale measures physical functional limitation while reflecting the behavioral avoidance of physical exertion. In respiratory illness, breathlessness often instigates a fear-avoidance spiral: patients systematically disengage from physical activity to circumvent dyspnea, leading to skeletal muscle deconditioning, exercise intolerance, and escalating disability.<\/p>\n The Impacts component constitutes the most psychologically complex dimension of the SGRQ, capturing the broader systemic, social, emotional, and existential consequences of airway disease. This dimension incorporates several critical psychological sub-facets:<\/p>\n The development and architectural taxonomy of the St. George\u2019s Respiratory Questionnaire are grounded in multidimensional conceptual frameworks of chronic disease, human disability, and health status assessment. Three foundational theoretical models underpin its construct validity:<\/p>\n The conceptual framework of the SGRQ aligns closely with the classification model proposed by Wilson and Cleary (1995)<\/a>, which links physiological variables, symptom status, functional status, general health perceptions, and overall quality of life into a causal continuum. In the SGRQ:<\/p>\n Grounded in the Biopsychosocial Model<\/a> formulated by George Engel, the SGRQ explicitly rejects biological reductionism. The questionnaire asserts that biological pathology (e.g., cellular airway remodeling or alveolar wall destruction) does not hold a linear relationship with patient suffering or personal handicap. Rather, psychological appraisal (such as catastrophic interpretations of dyspnea) and social contexts (interpersonal dependency, social support networks, public stigma) mediate how biological impairment translates into functional disability. By evaluating emotional distress, social disruption, and medication-related beliefs alongside physical symptoms, the SGRQ captures the broader lived experience of chronic illness.<\/p>\n The SGRQ incorporates principles from Leventhal’s Common-Sense Model of Self-Regulation<\/a>, which posits that patients construct cognitive and emotional representations of their illness. These cognitive representations include illness identity (symptoms), timeline (expecting the condition never to improve), consequences (loss of employment, domestic dependence), and control\/cure beliefs (believing medication does not help, feeling lacking in personal control). The Impacts domain of the SGRQ reflects these cognitive and emotional representations, demonstrating how negative cognitive representations exacerbate functional decline.<\/p>\n The psychometric validity of the St. George\u2019s Respiratory Questionnaire has been extensively evaluated across diverse patient cohorts, clinical trial populations, and international linguistic adaptations.<\/p>\n Construct validity was established in the initial validation studies by Jones et al. (1991, 1992) and confirmed in subsequent global trials. Convergent validity is demonstrated through predictable, moderate-to-strong correlations with both physiological measures and related patient-reported questionnaires:<\/p>\n The SGRQ demonstrates discriminant validity across differing stages of disease severity as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD<\/a>) criteria (GOLD Stages 1 through 4). Total and subscale SGRQ scores show statistically significant stepwise elevations across increasing GOLD stages (p<\/em> < 0.001). Furthermore, the instrument discriminates effectively between patients with frequent exacerbations (≥ 2 exacerbations per year) and non-frequent exacerbators, with frequent exacerbators demonstrating Total scores 8 to 14 points worse on average<\/span>.<\/p>\n Extensive prospective longitudinal studies have confirmed the predictive validity of the SGRQ for adverse clinical outcomes:<\/p>\n The SGRQ is sensitive to therapeutic change. In rehabilitation trials, surgical interventions, and pharmacological randomized controlled trials, the instrument detects both symptomatic improvements and disease deterioration. Through combined anchor-based and distribution-based psychometric techniques, the Minimal Clinically Important Difference<\/a> was established as a change of 4.0 units<\/strong>. A decrement of ≥ 4.0 points represents a clinically meaningful improvement, whereas an increase of ≥ 4.0 points indicates a clinically perceptible deterioration in health status<\/span>.<\/p>\n The St. George\u2019s Respiratory Questionnaire demonstrates strong reliability across diverse clinical populations, languages, and testing environments.<\/p>\n Internal consistency has been thoroughly documented across clinical investigations. Cronbach\u2019s alpha (α) coefficients routinely exceed established psychometric thresholds for group comparisons (α ≥ 0.70) and individual monitoring (α ≥ 0.90)<\/span>:<\/p>\n In clinically stable outpatients assessed at intervals ranging from 2 weeks to 4 weeks (in the absence of acute exacerbations or treatment alterations), the SGRQ exhibits high reproducibility:<\/p>\n The structural dimensionality of the SGRQ has been investigated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA), alongside Item Response Theory (IRT) and Rasch measurement models.<\/p>\n In the seminal psychometric work by Jones et al. (1991), candidate items were developed from qualitative clinical interviews with patients suffering from severe airflow limitation. Factor analytic evaluations using principal component analysis with orthogonal (Varimax) and oblique rotations consistently yielded a three-factor solution explaining between 45% and 55% of the total variance across the item pool:<\/p>\n Subsequent contemporary structural equation modeling studies evaluating the three-factor hierarchical model across international cohorts have demonstrated adequate model fit:<\/p>\n Application of Rasch measurement modeling and Item Response Theory (IRT) to the SGRQ by Meguro et al. (2007) and Jones (2012) identified minor psychometric anomalies within the original instrument, particularly when applied strictly to COPD populations. Several items in the Symptoms domain (such as items addressing wheezing worse in the morning or seasonal recall) displayed differential item functioning (DIF) or poor fit statistics. This work led to the development of the SGRQ-C (COPD-Specific Version)<\/strong>, a 40-item derivation in which 10 psychometrically weaker or asthma-specific items were removed, and the recall period was standardized, achieving improved unidimensional fit within individual domains while preserving structural equivalence to the original instrument.<\/p>\n The standard SGRQ is structured as follows:<\/p>\n The St. George\u2019s Respiratory Questionnaire was originally published in 1991 (with extensive validation published in 1992) by Professor Paul W. Jones at St George\u2019s Hospital Medical School, University of London. The COPD-specific shortened variant, the SGRQ-C, was published in 2012.<\/p>\n Copyright and Licensing:<\/strong> The SGRQ, SGRQ-C, and their official translations are protected under international copyright owned by St George\u2019s, University of London<\/strong>. Commercial pharmaceutical clinical trials, contract research organizations (CROs), and funded commercial entities must obtain a formal user license and pay associated licensing and distribution fees. Academic researchers, non-funded clinical investigators, and routine clinical healthcare services may typically access the questionnaire and scoring software under royalty-free or discounted academic licenses, subject to formal registration and approval.<\/p>\n Distribution and Access:<\/strong> Licensing, official linguistic validations, and scoring spreadsheets are managed and distributed via the Mapi Research Trust \/ ePROVIDE platform<\/a>. Users must register their study protocol, sign a user agreement, and utilize verified translations to ensure data integrity and prevent copyright infringement.<\/p>\nKeywords<\/h2>\n
Authors<\/h2>\n
\n
Purpose<\/h2>\n
Psychological Construct<\/h2>\n
1. The Symptoms Domain<\/h3>\n
2. The Activity Domain<\/h3>\n
3. The Impacts Domain<\/h3>\n
\n
Theoretical Framework<\/h2>\n
The Wilson and Cleary Model of Health-Related Quality of Life<\/h3>\n
\n
The Biopsychosocial Model of Illness<\/h3>\n
Leventhal\u2019s Common-Sense Model of Self-Regulation<\/h3>\n
Validity<\/h2>\n
Construct and Convergent Validity<\/h3>\n
\n
Discriminant and Known-Groups Validity<\/h3>\n
Predictive Validity<\/h3>\n
\n
Responsiveness and Minimal Clinically Important Difference (MCID)<\/h3>\n
Reliability<\/h2>\n
Internal Consistency<\/h3>\n
\n
Test-Retest Reliability and Stability<\/h3>\n
\n
Factor Analysis<\/h2>\n
Original Factor Structure and Scaling<\/h3>\n
\n
Confirmatory Factor Analysis (CFA) and Goodness-of-Fit<\/h3>\n
\n
Rasch Analysis and the Development of the SGRQ-C<\/h3>\n
Instrument \/ Measurement Tool<\/h2>\n
\n
\n
\n
\n
\n
\n Score = 100 × (∑ weights of positive responses) \/ (∑ maximum possible weights for answered items)<\/code>\n <\/li>\nPermissions & Fee and Test Year<\/h2>\n
References<\/h2>\n
\n
13. Items of the Scale (Questionnaire)<\/h2>\n